Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study
- Autori: Trama A.; Foschi R.; Larranaga N.; Sant M.; Fuentes-Raspall R.; Serraino D.; Tavilla A.; Eycken L.V.; Nicolai N.; Hackl M.; Zielonke N.; Oberaigner W.; Eycken E.V.; Henau K.; Valerianova Z.; Dimitrova N.; Sekerija M.; Zvolsky M.; Dusek L.; Storm H.; Engholm G.; Magi M.; Aareleid T.; Malila N.; Seppa K.; Velten M.; Troussard X.; Bouvier V.; Launoy G.; Guizard A.V.; Faivre J.; Bouvier A.M.; Arveux P.; Maynadie M.; Woronoff A.S.; Robaszkiewicz M.; Baldi I.; Monnereau A.; Tretarre B.; Bossard N.; Belot A.; Colonna M.; Molinie F.; Bara S.; Schvartz C.; Lapotre-Ledoux B.; Grosclaude P.; Meyer M.; Stabenow R.; Luttmann S.; Eberle A.; Brenner H.; Nennecke A.; Engel J.; Schubert-Fritschle G.; Kieschke J.; Heidrich J.; Holleczek B.; Katalinic A.; Jonasson J.G.; Tryggvadottir L.; Comber H.; Mazzoleni G.; Bulatko A.; Buzzoni C.; Giacomin A.; Sardo A.S.; Mazzei A.; Ferretti S.; Crocetti E.; Manneschi G.; Gatta G.; Amash H.; Amati C.; Baili P.; Berrino F.; Bonfarnuzzo S.; Botta L.; Salvo F.D.; Margutti C.; Meneghini E.; Minicozzi P.; Zucchetto A.; Angelis R.D.; Caldora M.; Capocaccia R.; Carrani E.; Francisci S.; Mallone S.; Pierannunzio D.; Roazzi P.; Rossi S.; Santaquilani M.; Pannozzo F.; Busco S.; Bonelli L.; Vercelli M.; Gennaro V.; Ricci P.; Autelitano M.; Randi G.; Ponz De Leon M.; Marchesi C.; Cirilli C.; Fusco M.; Vitale M.F.; Usala M.; Traina A.; Zarcone M.; Vitale F.; Cusimano R.; Michiara M.; Tumino R.; Rossi P.G.; Vicentini M.; Falcini F.; Iannelli A.; Sechi O.; Cesaraccio R.; Piffer S.; Madeddu A.; Tisano F.; Maspero S.; Fanetti A.C.; Zanetti R.; Rosso S.; Candela P.; Scuderi T.; Stracci F.; Rocca A.; Tagliabue G.; Contiero P.; Tos A.P.D.; Tognazzo S.; Pildava S.; Smailyte G.; Calleja N.; Micallef R.; Johannesen T.B.; Rachtan J.; Gozdz S.; Gozdz R.; Me zyk J.; Kepska K.; Bielska-Lasota M.; Forjaz de Lacerda G.; Bento M.J.; Antunes L.; Miranda A.; Mayer-Da-silva A.; Nicula F.; Coza D.; Diba C.S.; Primic-Zakelj M.; Almar E.; Mateos A.; Errezola M.; Torrella-Ramos A.; Garcia J.M.D.; Marcos-Navarro A.I.; Marcos-Gragera R.; Vilardell L.; Sanchez M.J.; Molina E.; Navarro C.; Chirlaque M.D.; Moreno-Iribas C.; Ardanaz E.; Galceran J.; Carulla M.; Lambe M.; Khan S.; Mousavi M.; Bouchardy C.; Usel M.; Ess S.M.; Frick H.; Lorez M.; Herrmann C.; Bordoni A.; Spitale A.; Konzelmann I.; Visser O.; Aben K.; Coleman M.; Allemani C.; Rachet B.; Verne J.; Easey N.; Lawrence G.; Moran T.; Rashbass J.; Roche M.; Wilkinson J.; Gavin A.; Fitzpatrick D.; Brewster D.H.; Huws D.W.; White C.
- Anno di pubblicazione: 2015
- Tipologia: Articolo in rivista
- Parole Chiave: Cancer registries; Penile cancers; Prostate; Survival; Survival trends; Testicular
- OA Link: http://hdl.handle.net/10447/414825
Abstract
Background We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. Methods The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000-2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999-2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. Results We analysed 1,021,275 male genital cancer cases. Five-year relative survival was high and decreased with increasing age for all tumours considered. We found limited variation in survival between European regions with Eastern Europe countries having lower survival than the others. Survival for penile cancer patients did not improve from 1999 to 2007. Survival for testicular cancer patients remained stable at high levels since 1999. Survival for prostate cancer patients increased over time. Conclusions Treatment standardisation and centralisation for very rare diseases such as penile cancers or advanced testicular tumours should be supported. The high survival of testicular cancer makes long-term monitoring of testicular cancer survivors necessary and CRs can be an important resource. Prostate cancer patients' survival must be interpreted considering incidence and mortality data. The follow-up of the European Randomised Study of Screening for Prostate Cancer should continue to clarify the impact of screening on prostate cancer mortality together with population based studies including information on stage and treatments.